Viatris’ Mylan Pharmaceuticals and Sun Pharmaceuticals have become the latest targets in lawsuits filed by Novo Nordisk as part of its strategy to fend off the entry of Wegovy (semaglutide) generics into the lucrative US market.
Novo Nordisk Sues Viatris’ Mylan And Sun Pharma Over Wegovy Generics
The Complaint Focuses On The Encroachment Of The ‘779 Patent
Amid ongoing supply challenges and neverending demand for semaglutide, Novo Nordisk has filed two complaints in the District Court of Delaware seeking permanent injunctions against Viatris’ Mylan and Sun.
More from Generics
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.